Forma de presentación | 14 JUN 06

Revisión del síndrome del glucagonoma

El eritema migratorio necrolítico es la forma de presentación de casi el 70% de los glucagonomas.
Autor: Andre P van Beek, Ellen R M de Haas, Willem A van Vloten, Cees J M Lips, Janine F M Roijers and Mari Fuente: Traducción y resumen objetivo: Dra. Marta Papponetti Archives of Dermatology and Syphilology 1942 45 1069–1080.
INDICE:  1. Desarrollo | 2. Bibliografía
Bibliografía
1. 1 Becker SW, Kahn D & Rothman S. Cutaneous manifestations of internal malignant tumors. Archives of Dermatology and Syphilology 1942 45 1069–1080.
2. 2 McGavran MH, Unger RH & Recant L. A glucagon-secreting alpha-cell carcinoma of the pancreas. New England Journal of Medicine 1966 274 1408–1413.
3. 3 Wilkinson DS. Necrolytic migratory erythema with carcinoma of the pancreas. Transactions of the St John’s Hospital Dermatological Society 1973 59 244–250.
4. 4 Wilkinson DS. Necrolytic migratory erythema with pancreatic carcinoma. Proceedings of the Royal Society of Medicine 1971 64 1197.
5. 5 Wermers RA, Fatourechi V, Wynne AG, Kvols LK & Lloyd RV. The glucagonoma syndrome. Clinical and pathologic features in 21 patients. Medicine 1996 75 53–63.
6. 6 Edney JA, Hofmann S, Thompson JS & Kessinger A. Glucagonoma syndrome is an underdiagnosed clinical entity. American Journal of Surgery 1990 160 625–628.
7. 7 Wermers RA, Fatourechi V & Kvols LK. Clinical spectrum of hyperglucagonemia associated with malignant neuroendocrine tumors. Mayo Clinic Proceedings 1996 71 1030–1038.
8. 8 Akerstrom G, Hessman O & Skogseid B. Timing and extent of surgery in symptomatic and asymptomatic neuroendocrine tumors of the pancreas in MEN 1. Langenbeck’s Archives of Surgery 2002 386 558–569.
9. 9 Geerdink E, Van der Luijt RB & Lips CJ. Do patients with multiple endocrine neoplasia syndrome type 1 benefit from periodical screening? European Journal of Endocrinology 2003 149 577–582.
10. 10 Stacpoole PW. The glucagonoma syndrome: clinical features, diagnosis, and treatment. Endocrine Reviews 1981 2 347–361.
11. 11 Rosenberg PM & Goldfinger SE. Glucagonoma and the glucagonoma syndrome. In UptoDate 2004 online 11.3.
12. 12 Nightingale KJ, Davies MG & Kingsnorth AN. Glucagonoma syndrome: survival 24 years following diagnosis. Digestive Surgery 1999 16 68–71.
13. 13 Altimari AF, Bhoopalam N, O’Dorsio T, Lange CL, Sandberg L & Prinz RA. Use of a somatostatin analog (SMS 201-995) in the glucagonoma syndrome. Surgery 1986 100 989–996.
14. 14 Faiss S, Pape UF, Bohmig M, Dorffel Y, Mansmann U, Golder W, Riecken EO &Wiedenmann B. Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa,
15. and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors – the International Lanreotide and Interferon Alfa Study Group. Journal of Clinical Oncology 2003 21 2689–2696.
16. 15 Alexander EK, Robinson M, Staniec M & Dluhy RG. Peripheral amino acid and fatty acid infusion for the treatment of necrolytic migratory erythema in the glucagonoma syndrome. Clinical Endocrinology 2002 57 827–831.
17. 16 Bewley AP, Ross JS, Bunker CB & Staughton RC. Successful treatment of a patient with octreotide-resistant necrolytic migratory erythema. British Journal of Dermatology 1996 134 1101–1104.
18. 17 Chastain MA. The glucagonoma syndrome: a review of its  features and discussion of new perspectives. American Journal of the Medical Sciences 2001 321 306–320.
19. 18 Binnick AN, Spencer SK, Dennison WL Jr & Horton ES. Glucagonoma syndrome. Report of two cases and literature review. Archives of Dermatology 1977 113 749–754.
20. 19 Haneke E. Acquired zinc deficiency mimicking glucagonoma dermatitis. Histology and electron microscopy. Zeitschrift fur Hautkrankheiten 1984 59 902–908.
21. 20 Hoitsma HF, Cuesta MA, Starink TM, Uttendorfsky-van der Putten HJ & van der Veen EA. Zinc deficiency syndrome versus glucagonoma syndrome. Archivum Chirurgicum Neerlandicum 1979 31 131–140.
22. 21 El Darouti M & Abu eE. Necrolytic acral erythema: a cutaneous marker of viral hepatitis C. International Journal of Dermatology 1996 35 252–256.
23. 22 Hendricks WM. Pellagra and pellagra like dermatoses: etiology, differential diagnosis, dermatopathology, and treatment. Seminars in Dermatology 1991 10 282–292.
24. 23 Stratigos JD & Katsambas AD. Pellagra: ‘A reappraisal’. Acta Vitaminologica et Enzymologica 1982 4 115–121.
25. 24 Graves K, Kestenbaum T & Kalivas J. Hereditary acrodermatitis enteropathica in an adult. Archives of Dermatology 1980 116 562–564.
26. 25 Tanaka S, Yamasaki S, Matsushita H, Ozawa Y, Kurosaki A, Takeuchi K, Hoshihara Y, Doi T, Watanabe G & Kawaminami K. Duodenal somatostatinoma: a case report and review of 31 cases with special reference to the relationship between tumor size and metastasis. Pathology International 2000 50
27. 146–152.
28. 26 Holst JJ. Enteroglucagon. Annual Review of Physiology 1997 59 257–271.
29. 27 Drucker DJ. Glucagon and the glucagon-like peptides. Pancreas 1990 5 484–488.
30. 28 Gillet M, Rodier C, Quencez E, Laurent R, Mantion G, Landecy G, Nguyen N & Carbillet JP. Pancreatic tumor with diabetes and necrotic migratory erythema. Glucagonoma or proglucagonoma? Chirurgie 1988 114 441–446.
31. 29 Rindi G, Efrat S, Ghatei MA, Bloom SR, Solcia E & Polak JM. Glucagonomas of transgenic mice express a wide range of general neuroendocrine markers and bioactive peptides. Virchows Archives A Pathological Anatomy and Histopathology 1991 419 115–129.
32. 30 Hamid QA, Bishop AE, Sikri KL, Varndell IM, Bloom SR & Polak JM. Immunocytochemical characterization of 10 pancreatic tumours, associated with the glucagonoma syndrome, using antibodies to separate regions of the pro-glucagon molecule and other neuroendocrine markers. Histopathology 1986 10 119–133.
33. 31 Keller U, Fankhauser S, Schumacher A, Trimble ER & Heitz PU. Glucagonoma syndrome in a multihormonal pancreatic tumor. Schweizerische Medizinische Wochenschrift 1982 112 297–304.
34. 32 Almdal TP, Heindorff H, Bardram L & Vilstrup H. Increased amino acid clearance and urea synthesis in a patient with glucagonoma. Gut 1990 31 946–948.
35. 33 Barazzoni R, Zanetti M, Tiengo A & Tessari P. Protein metabolism in glucagonoma. Diabetologia 1999 42 326–329. 34 Boden G, Rezvani I & Owen OE. Effects of glucagon on plasma amino acids. Journal of Clinical Investigation 1984 73 785–793.
36. 35 Tessari P, Inchiostro S, Barazzoni R, Zanetti M, Vettore M, Biolo G, Iori E, Kiwanuka E & Tiengo A. Hyperglucagonemia stimulates phenylalanine oxidation in humans. Diabetes 1996 45 463–470. 36 Prendiville JS & Manfredi LN. Skin signs of nutritional disorders. Seminars in Dermatology 1992 11 88–97.
37. 37 Larsen PJ, Vrang N & Tang-Christensen M. Central pre-proglucagon derived peptides: opportunities for treatment of obesity. Current Pharmaceutical Design 2003 9 1373–1382.
38. 38 Drucker DJ, Boushey RP, Wang F, Hill ME, Brubaker PL & Yusta B. Biologic properties and therapeutic potential of glucagon-like peptide- 2. Journal of Parenteral and Enteral Nutrition 1999 23 S98–S100.
39. 39 McGregor GP, Goke R & Goke B. Biological actions of glucagon-like peptide(GLP)-2 revealed – how pluripotential is the glucagons gene? Experimental and Clinical Endocrinology and Diabetes 1998
40. 106 25–28.
41. 40 Degn KB, Juhl CB, Sturis J, Jakobsen G, Brock B, Chandramouli V, Rungby J, Landau BR & Schmitz O. One week’s treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose relaease in patients with type 2 diabetes. Diabetes 2004 53 1187–1194.
42. 41 Moran TH. Pancreatic polypeptide: more than just another gut hormone? Gastroenterology 2003 124 1542–1544.
43. 42 Asakawa A, Inui A, Yuzuriha H, Ueno N, Katsuura G, Fujimiya M, Fujino MA, Niijima A, Meguid MM & Kasuga M. Characterization of the effects of pancreatic polypeptide in the regulation of energy balance. Gastroenterology 2003 124 1325–1336.
44. 43 Mullans EA & Cohen PR. Iatrogenic necrolytic migratory erythema: a case report and review of nonglucagonoma-associated necrolytic migratory erythema. Journal of the American Academy of Dermatology 1998 38 866–873.
45. 44 Wald M, Lawrenz K, Luckner D, Seimann R, Mohnike K & Schober E. Glucagon therapy as a possible cause of erythema necrolyticum migrans in two neonates with persistent hyperinsulinaemic hypoglycaemia. European Journal of Pediatrics 2002 161 600–603.
46. 45 Case CC & Vassilopoulou-Sellin R. Reproduction of features of the glucagonoma syndrome with continuous intravenous glucagons infusion as therapy for tumor-induced hypoglycemia. Endocrine Practice 2003 9 22–25.
 

Comentarios

Usted debe ingresar al sitio con su cuenta de usuario IntraMed para ver los comentarios de sus colegas o para expresar su opinión. Si ya tiene una cuenta IntraMed o desea registrase, ingrese aquí